Morgan Rouprêt, ESOU22: Impact of Immune Checkpoint Inhibitors on the Treatment of Bladder, Prostate and Kidney Cancer

Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]

As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of […]

PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall […]